| Mar'19 | Dec'18 | Sep'18 | Jun'18 | Dec'17 | Dec'16 | |
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
94,513 | 27,784 | 45,974 | 41,576 | 129,404 | 10,122 | |
Marketable securities | ||||||
58,944 | 136,385 | 54,800 | 69,785 | 0 | - | |
Research and development credit | ||||||
8,661 | 8,268 | - | - | 1,753 | - | |
Prepaid expenses and other current assets | ||||||
5,712 | 6,605 | 6,219 | 4,637 | 3,685 | 4,110 | |
Research and development tax credit | ||||||
- | - | 6,284 | 4,595 | - | - | |
Total current assets | ||||||
167,830 | 179,042 | 113,277 | 120,593 | 134,842 | 14,232 | |
Property and equipment, net | ||||||
489 | 562 | 534 | 380 | 355 | 363 | |
Other assets | ||||||
1,414 | 409 | 632 | 215 | - | - | |
Total assets | ||||||
169,733 | 180,013 | 114,443 | 121,188 | 135,197 | 14,595 | |
Liabilities and shareholders’ equity | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
2,976 | 3,017 | 4,424 | 3,369 | 3,196 | 1,229 | |
Accrued expenses and other liabilities | ||||||
16,686 | 11,360 | 10,339 | 8,752 | 6,189 | 4,322 | |
Total current liabilities | ||||||
19,662 | 14,377 | 14,763 | 12,121 | 9,385 | 5,551 | |
Long-term lease obligations | ||||||
351 | - | - | - | - | - | |
Total liabilities | ||||||
20,013 | 14,377 | 14,763 | 12,121 | 9,385 | 5,551 | |
Commitments and contingencies (see Note 12) | ||||||
- | - | 0 | 0 | - | 0 | |
Shareholders’ equity: | ||||||
Ordinary shares, £0.01 nominal value; 100,000 shares authorized as of March 31, 2019 and December 31, 2018; 33,484 and 33,486 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively | ||||||
61 | 61 | 1 | 1 | 1 | - | |
Additional paid-in capital | ||||||
268,967 | 267,233 | 188,949 | 187,987 | 185,943 | 43,478 | |
Accumulated other comprehensive income (loss): | ||||||
Cumulative foreign currency translation adjustment | ||||||
-4,855 | -4,855 | - | - | 1,890 | - | |
Unrealized holding gains on available for sales securities | ||||||
823 | 2,081 | - | - | - | - | |
Total accumulated other comprehensive loss | ||||||
-4,032 | -2,774 | 1,226 | 5,555 | 1,890 | -2,098 | |
Accumulated deficit | ||||||
-115,276 | -98,884 | -90,496 | -84,476 | -62,022 | -32,336 | |
Total shareholders’ equity | ||||||
149,720 | 165,636 | 99,680 | 109,067 | 125,812 | 9,044 | |
Total liabilities and shareholders’ equity | ||||||
169,733 | 180,013 | 114,443 | 121,188 | 135,197 | 14,595 | |